NEU 0.88% $19.80 neuren pharmaceuticals limited

Deal Pending, page-178

  1. 128 Posts.
    lightbulb Created with Sketch. 3
    Hi SMDM,
    I like your question (and concern).
    I had very similar concerns re VLA and asked at one of their AGM’s.
    Was told that it is potentially quite easy to overcome. In the case of NEU, if there is a sale transaction, there would be clauses adding extra payments should Trof prove helpful for other indications.
    On the other hand, if the final transaction is a licensing one (my preferred option), there are no issues at all. If Trof helps other conditions, Sales will increase and so will amount coming to Neuren.
    Have great day.

    Rgds
    KMS
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.